0001209191-19-048892.txt : 20190909 0001209191-19-048892.hdr.sgml : 20190909 20190909162001 ACCESSION NUMBER: 0001209191-19-048892 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190906 FILED AS OF DATE: 20190909 DATE AS OF CHANGE: 20190909 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sheridan John F CENTRAL INDEX KEY: 0001365369 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 191083247 MAIL ADDRESS: STREET 1: C/O TANDEM DIABETES CARE, INC. STREET 2: 11045 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-06 0 0001438133 TANDEM DIABETES CARE INC TNDM 0001365369 Sheridan John F C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET SAN DIEGO CA 92121 0 1 0 0 PRESIDENT & CEO Common Stock 2019-09-06 4 M 0 9538 2.59 A 12039 D Common Stock 2019-09-06 4 S 0 9538 70.03 D 2501 D Stock Option 2.59 2019-09-06 4 M 0 9538 0.00 D Common Stock 9538 32129 D Represents shares of common stock received upon exercise of a stock option award. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2019. The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $70.05. The reporting person undertakes to provide the SEC, the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter The expiration date for these options is ten (10) years from the date of grant. /s/David B. Berger, Attorney-in-Fact for John F. Sheridan 2019-09-09